Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10302060 | 1.00 | SCN9A (0.32) | SCN9AOPRL1CNR1CNR2LTC4S | |
| SCHEMBL10302061 | 0.97 | CNR2 (0.33) | SCN9AOPRL1CNR1CNR2LTC4S | |
| SCHEMBL11933156 | 0.96 | CTSL (0.33) | SCN9AOPRL1FFAR4 | |
| SCHEMBL11933281 | 0.96 | CTSL (0.33) | SCN9AOPRL1FFAR4 | |
| SCHEMBL10302064 | 0.96 | CNR2 (0.34) | OPRL1CNR1CNR2ESR1 | |
| SCHEMBL10302062 | 0.96 | CNR2 (0.34) | OPRL1CNR1CNR2ESR1 | |
| SCHEMBL10302063 | 0.96 | CNR2 (0.34) | OPRL1CNR1CNR2ESR1 | |
| SCHEMBL14922511 | 0.94 | SCN9A (0.35) | SCN9AOPRL1CNR1CNR2PPARG | |
| SCHEMBL12196728 | 0.93 | CTSL (0.31) | FFAR4 | |
| SCHEMBL14922539 | 0.92 | SCN9A (0.34) | SCN9ACNR1CNR2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | SCN9A 2120/4885OPRL1 1746/4885CNR1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.